Updated:
ChargePoint Technology
ChargePoint Technology is a other based in Liverpool; the Altss profile covers its classification, headquarters, registration, AUM band, and key contacts for...
ChargePoint Technology
ChargePoint Technology specialises in pharmaceutical containment & aseptic processing with patented powder transfer systems
General information
Firm type
other
Location
Region
Europe
Country
United Kingdom
City
Liverpool
Corporate office
Liverpool, United Kingdom
Additional offices
New Jersey, United States · Boston, United States
Frequently asked questions
What is the core product technology at ChargePoint Technology?
ChargePoint Technology's core product is a split butterfly valve for high-containment and aseptic powder transfer, originally developed in 1997 with Glaxo Pharmaceuticals (now GSK). The company also produces single-use powder packaging bags (ChargeBag® PE-S and ChargeBag® XL), fluid management systems (Terracon™ and TerraPure®), and robotic powder-handling equipment.
What industries does ChargePoint Technology serve?
ChargePoint Technology serves the pharmaceutical, biopharmaceutical, and life science industries. Its equipment is used for handling potent active pharmaceutical ingredients (APIs), aseptic processing, and sterile powder transfer in drug manufacturing.
Where is ChargePoint Technology headquartered and what are its other locations?
ChargePoint Technology is headquartered at Venture Point Business Park, Liverpool, United Kingdom. It also has sales and service offices in New Jersey, United States, and a manufacturing, sales, and service facility in Boston, Massachusetts, operating as Terracon Corp.
Does ChargePoint Technology offer after-sales support?
Yes, ChargePoint Technology operates an AfterCare team that provides installation support, spare parts, tailored maintenance packages, training, and local engineering support for its powder transfer systems.
How does ChargePoint Technology ensure compliance with pharmaceutical regulations?
ChargePoint Technology designs its products to meet regulatory standards for containment and sterility assurance, including Annex 1 guidelines for aseptic processing. In May 2026, the company published guidance on navigating Annex 1 compliance challenges.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: